3Q EARNINGS: J&J's drug sales jump 10% on Zytiga, Xarelto, other new products
This article was originally published in Scrip
At one point during Johnson & Johnson’s quarterly earnings call, chief financial officer Dominic Caruso was asked if the health care conglomerate would consider breaking up its businesses to “unleash the value” of its fast-growing drug division.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.